Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT01602380 2026-02-27

FALCON

Phase 3 Completed

462 enrolled 20 charts

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT04059484 2026-02-24

AMEERA-3

Phase 2 Terminated

367 enrolled 30 charts

Breast

Breast Cancer Metastatic

NCT06905301 2026-02-20

IMPULSE

Recruiting

240 enrolled

Breast

Breast Neoplasms

NCT02763566 2026-02-05

MONARCH plus

Phase 3 Active not recruiting

463 enrolled 20 charts

Breast

Breast Neoplasms

NCT02246621 2026-02-03

MONARCH 3

Phase 3 Active not recruiting

493 enrolled 23 charts 1 FDA

Breast

Breast Neoplasms

NCT05161195 2026-02-02

Roll-over Study to Allow Continued Access to Ribociclib

Phase 4 Active not recruiting

134 enrolled

Breast

Breast Neoplasms

NCT05514054 2026-01-29

EMBER-4

Phase 3 Active not recruiting

8,000 enrolled

Breast

Breast Neoplasms

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Phase 1 Active not recruiting

198 enrolled

Breast

Breast Neoplasms

NCT02779751 2026-01-26

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

Phase 1 Active not recruiting

100 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04964934 2026-01-16

SERENA-6

Phase 3 Active not recruiting

315 enrolled

Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT04906395 2026-01-13

OVELIA

Phase 3 Active not recruiting

250 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT05645536 2026-01-12

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Phase 3 Enrolling by invitation

250 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT04556773 2025-12-17

DB-08

Phase 1 Active not recruiting

138 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06495164 2025-11-25

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

Active not recruiting

1 enrolled

Breast

Breast Neoplasms

NCT06086340 2025-11-18

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Completed

779 enrolled 9 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03671330 2025-10-31

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

Phase 2 Completed

327 enrolled

Breast

Breast Neoplasms

NCT03822468 2025-10-16

AMALEE

Phase 2 Completed

376 enrolled 17 charts

Breast

Breast Neoplasms

NCT04711252 2025-10-14

SERENA-4

Phase 3 Active not recruiting

1,370 enrolled

Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Skin Diseases

NCT03778931 2025-09-15

EMERALD

Phase 3 Completed

478 enrolled 16 charts 1 FDA

Breast

Breast Neoplasms

NCT05549505 2025-08-29

A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery

Phase 2 Completed

152 enrolled 16 charts

Breast

Breast Neoplasms

NCT05257395 2025-07-17

A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer

Phase 3 Active not recruiting

397 enrolled

Breast

Breast Neoplasms

NCT03099174 2025-06-24

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

Phase 1 Completed

133 enrolled 26 charts

Breast

Breast Neoplasms, Neoplasms

NCT05952557 2025-06-19

CAMBRIA-2

Phase 3 Recruiting

5,500 enrolled

Breast

Breast Neoplasms

NCT06957379 2025-05-04

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

Phase 2 Active not recruiting

78 enrolled

Breast

Breast Neoplasms

Clinical Trials

RAMP 301

ELEGANCE

OPERA-01

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

PIKASSO-01

PIKALO-1

FALCON

AMEERA-3

IMPULSE

MONARCH plus

MONARCH 3

Roll-over Study to Allow Continued Access to Ribociclib

EMBER-4

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

SERENA-6

OVELIA

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

DB-08

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

AMALEE

SERENA-4

EMERALD

A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery

A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

CAMBRIA-2

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy